Pay in 4 interest-free payments of $5.50 Learn more
Ships within 48 hours · Estimated delivery Oct 15 - Oct 20
Key Milestones Timeline Eli Lillys Strategic Context Retatrutides development occurs within Eli Lillys broader metabolic disease portfolio, which also includes tirzepatide (approved as Mounjaro for type 2 diabetes and Zepbound for obesity) and orforglipron (an oral GLP-1R agonist in Phase 3 development)
If you are ready to see whether a personalized program is the right fit, you can take the free assessment quiz
This REMS is called iPLEDGE
Retatrutide solution, like most authorised incretin-based injectable peptides, is expected to appear as a clear, colourless to slightly yellow liquid when in good condition
Build strength
US$ 20.95
US$ 23.08
US$ 21.32
.png.jpg)
US$ 24.66
